Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Its lead product is ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis. The company is also developing F351 (Hydronidone), a structural derivative of ETUARY, which is in Phase 3 trials for chronic hepatitis B-associated liver fibrosis and has completed Phase 1 trials for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. Additionally, Gyre has F573 in Phase 2 trials for acute/acute-on-chronic liver failure, and preclinical products F230 for pulmonary arterial hypertension and F528 for chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California.

Gyre Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol GYRE. The company trades in United States Dollars (USD), as it is based in the United States. Being listed on a major US exchange provides investors with liquidity and access to the company's stock through standard brokerage platforms.

Gyre Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for diseases with high unmet medical needs, particularly in the area of fibrosis. The company's work involves research, clinical trials, and regulatory processes to bring new drugs to market, targeting conditions such as idiopathic pulmonary fibrosis, liver fibrosis, and pulmonary arterial hypertension.

Gyre Therapeutics is headquartered in San Diego, California, United States. The company operates as a subsidiary of GNI USA, Inc. While its primary market is the United States, where ETUARY is approved for idiopathic pulmonary fibrosis, its pipeline includes treatments for conditions prevalent globally, such as chronic hepatitis B-associated liver fibrosis and pneumoconiosis. The company's clinical trials and potential future approvals could expand its reach to international markets.

Gyre Therapeutics generates revenue primarily through the commercialization of its approved drug, ETUARY (Pirfenidone), for the treatment of idiopathic pulmonary fibrosis. The company also invests in research and development of a pipeline of anti-fibrotic drugs, including F351, F573, F230, and F528, which are at various stages of clinical and preclinical development. If these candidates receive regulatory approval, they could provide additional revenue streams. As a biotechnology firm, Gyre may also enter into partnerships or licensing agreements to further develop or market its products. The company's focus on fibrosis, a condition with limited treatment options, positions it in a niche but potentially lucrative market.